LAUSR.org creates dashboard-style pages of related content for over 1.5 million academic articles.
Sign Up to like articles & get recommendations!
A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon‐like peptide‐1 receptor agonist, in healthy Japanese men with overweight/obesity
Photo from wikipedia
To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity. Click to show full abstract
To report a Phase I study of subcutaneous glucagon receptor (GCGR)/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist BI 456906 versus placebo in healthy Japanese men with overweight/obesity.
Share on Social Media:
  
        
        
        
Sign Up to like & get recommendations! 2
Related content
More Information
            
News
            
Social Media
            
Video
            
Recommended
               
Click one of the above tabs to view related content.